<< Предыдущая

стр. 3
(из 4 стр.)

ОГЛАВЛЕНИЕ

Следующая >>

ритонавиром для
существенного
снижения
чувствительности
требуется несколько
мутаций
Саквинавир G73S, V82F/S/T
? 4 из следующих
мутаций: L10I/ R/V,
G48V, I54V/L, A71V/T,
V77I, V82A, I84V и L90M
Нелфинавир D30N V82A/F/S/T и 2 или более следующих
мутаций: L10I, M36I, M46l/L,
l84A/V
I54V/L/M/T, A71V/T, V77I
N88S/D
L90M
Фосампренавир I50V (особенно с
M46I/L)
V32I плюс I47V
I54L/M
I84V
G73S
Фосампренавир/ ? 6 из следующих
ритонавир мутаций: L10F/I/V,
(700/100 мг 2 K20M/R, E35D, R41K,
раза в сутки) или I54V/L/M, L63P,
ампренавир/ V82A/F/T/S, I84V
ритонавир
(600/100 мг 2
раза в сутки)
Лопинавир/ ? 8 из следующих 5-7 из следующих мутаций: L10F/I/R/V,
мутаций: L10F/I/R/V, K20M/R, L24l, V32I, L33F, M46l/L,
ритонавир
K20M/R, L24l, V32I, I47V/A, I50V, F53L, l54L/T/V, L63P,
A71l/L/V/T, G73S, V82A/F/T, l84V, L90M
L33F, M46l/L, I47V/A,
I50V, F53L, l54L/T/V,
L63P, A71l/L/V/T, G73S,
V82A/F/T, l84V, L90M
I84V, N88S
Атазанавир и I50L – часто в
атазанавир/ сочетании с A71V -
ритонавир ? 3-4 из следующих
(300/100 мг 1 раз мутаций для не
в сутки) усиленного атазанавира
и ? 6 из следующих
мутаций для усиленного
атазанавира:
L10I/V/F, K20R/M/I, L24I,
L33I/F/V, M36I/L/V,
M46I/L, M48V, I54V/L,
L63P, A71V/T/I,
G73C/S/T/A, V82A/F/S/T,
I84V и L90M
Типранавир ? 3 из следующих L10I/V, K20M/L/T, M46I, I54V,
V82A/F/L/T
мутаций: L33I/F/V,
V82A/F/S/T, I84V, L90M
* Вторичные мутации в положениях 10, 20, 36, 63, 71, 77 и 93, расположенные вне активной области, могут усиливать
устойчивость, вызванную первичными мутациями.


Таблица 4. Мутации устойчивости к энфувиртиду (с изменениями по материалам
Группы исследований устойчивости ANRS – AC 11, сентябрь 2002 г.,
http://hiv.net/link.php?id=138, и Группы исследований мутаций лекарственной устойчивости
Общества борьбы со СПИДом США (Johnson 2004))
Ингибиторы Мутации устойчивости
слияния
Энфувиртид (T- G36A/D/E/S/V
20) 38A/M/E/K/V
Q40H/K/P/R/T
N42T/D/S
N43D/K/H/S
N42T+N43S
L44M
L45M/L/Q
Литература
1. Antoniou T, Park-Wyllie L, Tseng AL. Tenofovir: A nucleotide analog for the management of Human Immunodeficiency Virus Infection. Pharmacotherapy 2003; 23:29-
43. http://www.medscape.com/viewarticle/448280
2. Arasteh K, Golz J, Marcus U, et al. Deutsch-Osterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion (Stand Mai 2004).
http://www.rki.de/INFEKT/AIDS_STD/BR_LINIE/BR_LINIE.HTM?ART0405.HTM&1
3. Balotta C, Berlusconi A, Pan A, et al. Virologic and immunologic outcome in recent seroconverters bearing resistance-related mutations treated with NRTI or NRTI plus
PI regimens. Abstract 370, 7th ECCATH 1999, Lisbon, Portugal.
4. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic
antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Abstract LB8, 6th CROI 1999, Chicago, USA.
5. Beerenwinkel N, Daumer M, Oette M, et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Research, 2003, Vol. 31, No. 13
3850-3855. http://nar.oupjournals.org/cgi/content/full/31/13/3850
6. Brillant J, Klumpp K, Swallow S, Cammack N, Heilek-Snyder G. In vitro resistance development for a second-generation NNRTI: TMC125. Antivir Ther. 2004, 9:S20.
7. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in
ALTIS 2 ANRS trial. Antivir Ther 2002; 7:211-8. http://amedeo.com/lit.php?id=12487389
8. Castagna A, Danise A, Carini E et al. E-184V. Pilot study to evaluate immunological response to lamivudine monotherapy vs treatment interruption in failing HIV-1
infected subjects, harbouring the M184V mutation. Abstract WeOrB1286, 15th International AIDS Conference 2004; Bangkok, Thailand. http://www.aids2004.org/
9. Chaix C, Grenier-Sennelier C, Durant J, et al. Economic Evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the
VIRADAPT study. Abstract 105, 3rd International Workshop on HIV Drug Resistance and Treatment Strategies 1999, San Diego, CA, USA.
10. Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004; 64:
2101-24. http://amedeo.com/lit.php?id=15341507
11. Clavel F, Hance AJ. HIV Drug Resistance. N Engl J Med 2004; 350:1023-1035
12. Cohen C, Kessler H, Hunt S, et al. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001). Antiviral
Ther 2000, 5 (supl 3): 67. Abstract 84.
13. Colonno RJ, McLaren C and Kelleher T. Pathways to Atazanavir resistance in treatment-experienced patients on Atazanavir ontaining regimens. Abstract/Poster 3.1,
2nd European HIV Drug Resistance Workshop 2004, Rome, Italy.
14. Colonno RJ, Friborg J, Rose RE, et al. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-
containing regimens. Antiviral Ther 2002, 7:S4. Abstract 4.
15. Colonno RJ, Rose R, Ciani C, et al. Emerge of resistance and maintenance of susceptibility to other PI is associated with an I50L substitution in HIV protease. Abstract
597, 10th CROI 2003, Boston, USA.
16. Conradie F, Sanne I, Venter W, et al. Failure of lopinavir-ritonavir (Kaletra-)containing regimen in an antiretroviral-naive patient. AIDS 2004, 18:1041-1085.
17. Cooper D, Hall D, Jayaweera D, et al. Baseline phenotypic susceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor
experience (BI 1182.52). Abstract 596, 10th CROI 2003; Boston, USA.
18. Corzillius M, Muhlberger N, Sroczynski G, et al. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral
treatment for HIV. Antivir Ther. 2004; 9:27-36. http://amedeo.com/lit.php?id=15040534
19. Craig C, Goddard C, Whittaker L, et al. HIV-1 genotype and phenotype during dual therapy (NV15436 sub-study). Abstract 103, 7th ECCATH 1999, Lisbon, Portugal.
20. De Mendoza C, Gallego O, Soriano V. Mechanisms of resistance to antiviral drugs – clinical implications. AIDS Rev 2002, 4: 64-82.
http://amedeo.com/lit.php?id=12152520
21. De Mendoza C, Rodriguez C, Corral A, et al. Evidence for a different transmission efficiency of viruses with distinct drug-resistant genotypes. Abstract 130, XII
International HIV Drug Resistance Workshop 2003, Los Cabos, Mexico.
22. De Meyer S, Azijn H, Van Ginderen M, et al. In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as
compared with currently licensed protease inhibitors. Abstract 5, XI International HIV Drug Resistance Workshop 2002, Seville, Spain.
23. DeJesus E, Ive P, Schurmann D, et al. The Solo Study: Sustained virological response in subjects receiving GW433908/Ritonavir (908/R) with high viral load and low
CD4 cell counts at study entry. Poster presentation TuPeB 4503, 15th International AIDS Conference 2004; Bangkok, Thailand.
http://www.iasociety.org/ejias/show.asp?abstract_id=2168446/
24. Dezube BJ, Jacobs MS, Leoung G, et al. A second generation non-nucleoside reverse transcriptase inhibitor, AG1549, in patients with HIV-1: a phase I study. Abstract
200, 7th ECCAT 1999, Lisbon, Portugal.
25. Drake JW. Rates of spontaneous mutation among RNA viruses. PNAS 1993, 90:4171-4175. http://amedeo.com/lit.php?id=8387212
26. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-99.
http://amedeo.com/lit.php?id=10392984
27. Eberle J, Goebel FD, Postel N, et al. Amino acid changes in the HIV-1/gp41 HR1 region associated with ongoing viral replication selected by T-20 (enfuvirtide) therapy.
Abstract/Poster 43, 3rd European Conference on Viral Diseases 2004, Regensburg, Germany.
28. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J
Med 1995, 333:1662-1669. http://amedeo.com/lit.php?id=7477218
29. EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management:
recommendations for the European setting. AIDS 2001; 15:309-320. http://amedeo.com/lit.php?id=11273210
30. Farthing C, Khanlou H, Yeh V, et al. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC), and tenofovir DF (TDF)
in treatment naive HIV-infected patients. LB 46, 2nd IAS Meeting 2003, Paris, France.
31. Friend J, Parkin N, Liegler T, et al. Isolated Lopinavir Resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004, 18:1965-1970.
32. Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to
efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. LB H-1722a, 43rd ICAAC, Chicago, USA.
33. Garcia-Lerma JG, MacInnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R
mutation. J Virol. 2003;77:5685-5693. http://intapp.medscape.com/px/medlineapp/getdoc?pmi=12719561&cid=med
34. Gazzard B, Pozniak A, Arasteh K, et al. TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected
individuals with phenotypic NNRTI resistance. Abstract 4, 9th CROI 2002, Chicago, USA.
th
35. Gomes P, Diogo I, Goncalves MF, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. Abstract 46, 9 CROI 2002; Seattle,
Washington.
36. Grant GM, Liegler T, Spotts G, et al. Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco, 2000-2002. Abstract 120, XII International
HIV Drug Resistance Workshop , 2003, Los Cabos, Mexico.
37. Grossman Z, Istomin V, Averbuch D, et al; Israel AIDS Multi-Center Study Group. Genetic variation at NNRTI resistance-associated positions in patients infected with
HIV-1 subtype C. AIDS 2004a; 18: 909-15. http://amedeo.com/lit.php?id=15060438
38. Grossman Z., Paxinos EE,. Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of
resistance to nelfinavir. Antimicrob Agents Chemother 2004b; 48:2159-2165. http://amedeo.com/lit.php?id=15155216
nd
39. Hackett J Jr, Swanson P, Drews B, et al. Natural polymorphisms associated with resistance to protease inhibitors in non-subtype B HIV-1 strains. Abstract 814, 2 IAS
Conference on HIV Pathogenesis and Treatment; 2003, Paris, France.
40. Hanna GJ, Balaguera HU, Steger KA, et al. Drug-selected and non-clade B pol genotypes in chronically HIV-1-infected antiretroviral-naive adults: response to
antiretroviral therapy. Antiviral Ther. 2001, 6(suppl1):111-112. Abstract 144.
41. Harrigan PR, Stone C, Griffin P, et al. Resistance profile of the HIV type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination
therapy. J Infect Dis 2000, 181:912-920. http://amedeo.com/lit.php?id=10720512
42. Havlir DV, Gamst A, Eastman S, Richman DD. Nevirapine-resistant HIV: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996, 70:7894-
7899. http://amedeo.com/lit.php?id=8892912
43. Hicks C, Eron J, Lennox J, et al. Antiretroviral resistance among patients with primary HIV infection in the southeastern US – impact on treatment outcome. Abstract
502, 10th CROI 2003, Boston, USA.
44. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with Human Immunedeficiency Virus type1: Recommendations of an
International AIDS Society-US Panel. ClD 2003, 37:113-28. http://amedeo.com/lit.php?id=12830416
45. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of HIV type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995,
206:527-534. http://amedeo.com/lit.php?id=7831807
46. Jemsek J, Hutcherson P, and E Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily
triple nucleoside regimen of didanosine, lamivudine, and tenofovir. DF. Abstract 51, 11th CROI 2004, San Francisco, USA.
http://64.251.206.31/2004/AbstractSearch/AbstractSearch.aspx
47. Johnson VA, Brun-Vezinet F, Bonaventura C, et al. Update of the drug resistance mutations in HIV-1. Special contribution - drug resistance mutations in HIV. Top HIV
Med. 2004, 12 (4):119-124. http://www.iasusa.org/resistance_mutations/mutations_figures.pdf
48. Kempf D, Xu Y, Brun S, et al. Baseline genotype and phenotype do not predict response to ABT-378/Ritonavir in PI-experienced patients at 24 and 48 weeks. Abstract
731, 7th CROI 2000, San Francisco, USA.
49. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir
among viral isolates from protease inhibitor-experienced patients. J Virol 2001, 75:7462-9. http://amedeo.com/lit.php?id=11462018
Koh Y, Nakata H, Maeda K, et al. TMC114 (UIC96017): a novel nonpeptidic protease inhibitor potent against multi-PI resistant HIV in vitro. Abstract 553, 10th CROI
50.
2003, Boston, USA.
51. Kohlbrenner V, Hall D, Schapiro J, et al. Development of a tipranavir mutation score: analysis of protease mutations associated with phenotypic drug susceptibility and
antiviral response in Phase II clinical trials. Antivir Ther. 2004;9:S143. Abstract 19. http://www.aegis.com/conferences/13thHIVDrugResWkshop/Session_5.pdf
52. Lacey SF, Larder BA. Novel mutation (V75T) in HIV type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'- dideoxythymidine in cell culture. Antimicrob
Agents Chemother 1994, 38:1428-1432. http://amedeo.com/lit.php?id=7522429
53. Lafeuillade A, Tardy JC. Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. AIDS Rev 2003, 5:80-6.
http://amedeo.com/lit.php?id=12876897
54. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir,
lamivudine, and tenofovir: the tonus study. Abstract 52, 11th CROI 2004, San Francisco, USA. http://www.retroconference.org/2004/cd/Abstract/52.htm
55. Lanier ER, Kubota M, Yau L, et al. Diverse effects of NRTI-associated mutations on resistance to abacavir, stavudine and zidovudine in the ZORRO trial. Abstract
1761, 41st ICAAC 2001, Chicago, USA. http://hiv.net/link.php?id=27
56. Larder B, de Vroey V, Dehertogh P, et al. Predicting HIV-1 phenotypic resistance from genotype using a large phenotype-genotype relational database. Abstract 106,
7th ECCATH 1999, Lisbon, Portugal.
57. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
http://amedeo.com/lit.php?id=2479983
58. Larder BA, Bloor S. Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance. Antivir Ther 2001, 6:38.
59. Larder B, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14: 1943-8.
http://amedeo.com/lit.php?id=10997398
60. Little SJ, Holle S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
http://content.nejm.org/cgi/content/short/347/6/385
61. Loveday C, Devereux H, Huckett L, Johnson M. High prevalence of multiple drug resistance mutations in a UK HIV/AIDS patient population. AIDS 1999, 13: 627-628.
http://amedeo.com/lit.php?id=10203393
62. Loutfy MR, Montaner JSG, Raboud JM, et al. Genotypic resistance assay for entire gp-41 sequence with identification of gp-41 polymorphisms in enfuvirtide-na ve
patients and new gp-41 mutations in patients failing enfuvirtide. . Abstract WeOrB1292, 15th International AIDS Conference 2004; Bangkok, Thailand.
http://www.iasociety.org/ejias/show.asp?abstract_id=2173981
63. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol
2004; 78: 4628-37. http://amedeo.com/lit.php?id=15078945
64. Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in HIV type 1-infected patients: selection of four alternative viral
protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46:731-8.
http://aac.asm.org/cgi/content/full/46/3/731?view=full&pmid=11850255
65. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in HIV type 1 protease inhibitor-
experienced patients. Antimicrob Agents Chemother 2003; 47: 594-600. http://amedeo.com/lit.php?id=12543665
66. Marcelin A, Flandre P, Pavie J, et al. New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-
experienced patients from the randomized didanosine add on Jaguar study. Antivir Ther. 2004;9:S146.
67. Martinez-Picado J, Savara AV, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of HIV type 1. J Virol 1999, 73:3744-3752.
http://amedeo.com/lit.php?id=10196268
68. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of HIV type 1 variants with insertions or deletions in the reverse transcriptase
(RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001, 45:1836-42. http://amedeo.com/lit.php?id=11353634
69. Mayers D, Leith J, Valdez H, et al. Impact of three or four protease mutations at codons 33, 82, 84 and 90 on 2 week virological responses to tipranavir, lopinavir,
amprenavir and saquinavir all boosted by ritonavir in Phase 2B trial BI 1182.51. Antivir Ther. 2004;9:S163.
70. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by HIV reverse transcriptase
in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000, 44:3465-72.
http://amedeo.com/lit.php?id=11083661
71. Miller MD. TAMs and Tenofovir. AIDS Reviews 2004, 6:22-33. http://www.aidsreviews.com/2004/rev01/art_03.html
72. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides
Nucleic Acids 2001, 20:1025-8. http://amedeo.com/lit.php?id=11562951
Miller MD, White KL, Petropoulos CJ, et al. Decreased replication capacity of HIV-1 clinical isolates containing K65R or M184V RT mutations. Abstract 616, 10th CROI
73.
2003, Boston, USA.
74. Molina JM, Marcelin AG, Pavie J, et al. Didanosine in treatment-experienced HIV-infected patients: Results from a randomized double-blind study (AI454-176 Jaguar).
Abstract H-447, 43rd ICAAC 2003, Chicago, USA.
75. Monachetti A, Castagna A, Bagnarelli P. Genetic and Phenotypic Characteristics of Enfuvirtide-resistant HIV-1 Isolates Evolved in vivo after Long-term Treatment.
Abstract 660, 11th CROI 2004, San Francisco, USA. http://64.251.206.31/2004/AbstractSearch/AbstractSearch.aspx
76. Mueller SM, Daeumer M, Kaiser R, et al. Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug
resistance mutation L76V. Antiviral Therapy 2004, 9:S44. Abstract 38.
http://www.informedhorizons.com/resistance2004/Posters/POSTERS/Walter_teneriffa2004_poster38.pdf
77. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations:
analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001, 6:115-26. http://amedeo.com/lit.php?id=11491416
78. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal
therapy. AIDS 1999, 13:2349-59. http://amedeo.com/lit.php?id=10597776
79. Parikh U, Koontz, Sluis-Cremer N, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM.
Abstract 54, 11th CROI 2004; San Francisco, California, USA. http://www.retroconference.org/Search_Abstract_2004/AbstractSearch.aspx
80. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-
resistance. AIDS 2003, 17: 955-962. http://www.medscape.com/viewarticle/452700_print
81. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-
1586. http://amedeo.com/lit.php?id=8599114
82. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for HIV type 1. Antimicrob Agents Chemother 2000, 44:920-8.
http://amedeo.com/lit.php?id=10722492
Potts KE, Fujivara T, Sato A, et al. Antiviral activity and resistance profile of AG1549, a novel hiv-1 non-nucleoside reverse transcriptase inhibitor. Abstract 12, 6th CROI
83.
1999, Chicago, USA.
84. Prado JG, Wrin T, Beauchaine J, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16: 1009-17. 52.
http://amedeo.com/lit.php?id=11953467
85. Ross L, Parkin L, Chappey C, et al. HIV clinical isolates containing mutations representative of those selected after first line failure with unboosted GW433908 remain
sensitive to other protease inhibitors. Abstract 19, XII International HIV Drug Resistance Workshop 2003, Los Cabos, Mexico.
86. Ross L, Lim M, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance mutations in antiretroviral therapy (ART) naive HIV infected indivuduals.
Abstract H-173, 44th ICAAC 2004, Washinton, DC, USA.
Schmidt B, Walter H, Marcus U, et al. Cross-resistance to amprenavir in PI-treated patients. Abstract 276, 7th CROI 2000, San Francisco, USA.
87.
88. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical
samples. AIDS 2003; 17:1258-61. http://amedeo.com/lit.php?id=12819531
89. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in HIV type 1 RNA load and appearance of drug-resistant virus populations in persons treated with
lamivudine (3TC). J Infect Dism 1995, 171:1411-1419. http://amedeo.com/lit.php?id=7539472
90. Shulman NS, Winters MA, Shafer RW, et al. Subtile changes in susceptibility to stavudine predict virologic response to stavudine monotherapy after zidovudine
treatment. Antiviral Ther 2001, 6(Suppl 1):124. Abstract 124.
91. Sharma PL, Crumpacker CS. Decreased processivity of HIV type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative
analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999, 73:8448-56. http://amedeo.com/lit.php?id=10482597
92. Shafer RW, Iversen AK, Winters MA, et al. Drug resistance and heterogeneous long-term virologic responses of HIV type 1-infected subjects to zidovudine and
didanosine combination therapy. J Infect Dis 1995, 172:70-78. http://amedeo.com/lit.php?id=7541064
93. Shafer R. Stanford HIV RT and Protease Sequence Database 1998-2002a. http://hiv.net/link.php?id=28
94. Shafer R. Stanford HIV RT and Protease Sequence Database 1998-2002b. http://hiv.net/link.php?id=29
95. Shafer R. Stanford HIV RT and Protease Sequence Database 1998-2002c. http://hiv.net/link.php?id=30
96. Sugiura W, Matsuda Z, Yokomaku Y, et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency
virus type 1. Antimicrob Agents Chemother 2002; 46:708-715. http://amedeo.com/lit.php?id=11850252

<< Предыдущая

стр. 3
(из 4 стр.)

ОГЛАВЛЕНИЕ

Следующая >>